König, D; Schär, S; Vuong, D; Guckenberger, M; Furrer, K; Opitz, I; Weder, W; Rothschild, S I; Ochsenbein, A; Zippelius, A; Addeo, A; Mark, M; Eboulet, E I; Hayoz, S; Thierstein, S; Betticher, D C; Ris, H-B; Stupp, R; Curioni-Fontecedro, A; Peters, S; ... (2022). Corrigendum to 'Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials': [ESMO Open Volume 7, Issue 2, (2022), 100455]. ESMO open, 7(3), p. 100494. Elsevier 10.1016/j.esmoop.2022.100494
|
Text
1-s2.0-S2059702922001144-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (150kB) | Preview |
Item Type: |
Journal Article (Further Contribution) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Ochsenbein, Adrian, Früh, Martin |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2059-7029 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Pubmed Import |
Date Deposited: |
26 Apr 2022 11:01 |
Last Modified: |
05 Dec 2022 16:19 |
Publisher DOI: |
10.1016/j.esmoop.2022.100494 |
Related URLs: |
|
PubMed ID: |
35468561 |
BORIS DOI: |
10.48350/169509 |
URI: |
https://boris.unibe.ch/id/eprint/169509 |
Actions (login required)
 |
Edit item |